Antibody-Drug Conjugates in Non-Small Cell Lung Cancer: Where Are the Target and the Biomarker?
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 40293370.
- Also identified by DOI 10.1158/1078-0432.CCR-25-0839.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Antibody-drug conjugates are an emerging treatment of non-small cell lung cancer. Some do not require biomarkers, whereas others require mutations and/or protein expression. New diagnostic technologies give opportunities for better target identification and selection of patients. Combination therapies might broaden relevant patient populations but might call for combined biomarker selection paradigms. See related article by Trontzas et al., p. 2767.
Medical subject headings
- Carcinoma, Non-Small-Cell Lung
- Immunoconjugates
- Lung Neoplasms
- Biomarkers, Tumor